Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

EV Biologics, Inc. (YECO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.9500+0.0098 (+1.04%)
At close: 10:44AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9402
Open0.9300
BidN/A x N/A
AskN/A x N/A
Day's Range0.9300 - 0.9500
52 Week Range0.8500 - 6.3700
Volume4,150
Avg. Volume2,990
Market Cap26.989M
Beta (5Y Monthly)-2.10
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
  • ACCESSWIRE

    EV Biologics Updates on NFT Dividend

    NASHVILLE, TN / ACCESSWIRE / November 12, 2021 / EV Biologics Corp, (OTC PINK:YECO), today updated shareholders with further details about its NFT dividend.The Company is still awaiting approval from FINRA for the distribution of the dividend.

  • ACCESSWIRE

    EV Biologics Signs Listing Agreement With INX

    NASHVILLE, TN / ACCESSWIRE / November 11, 2021 / EV Biologics Corp, ("the Company"), OTC PINK:YECO, today confirmed that it has signed an agreement to list its common stock on the INX Securities ATS, a regulated alternative trading system operated by INX Securities, LLC. INX Securities, LLC is the FINRA-member broker-dealer subsidiary of INX Limited.

  • ACCESSWIRE

    EV Biologics Chief Medical Officer Publication on COVID-19 & Exosomes

    NASHVILLE, TN / ACCESSWIRE / October 28, 2021 / EV Biologics Corp, OTC Pink:YECO, today updated shareholders about a recent publication authored by its Chief Medical Officer, Dr.This review discusses some of the cellular and molecular pathology of COVID-19 and the relevant therapeutic mechanisms of small extracellular vesicles (EVs), such as exosomes, in Acute Lung Injury (ALI).

Advertisement
Advertisement